PSCA (Prostate Stem Cell Antigen 2)

We review their molecular biology, preclinical validation, clinical translation, and ongoing trials. These biomarkers represent diverse biological compartments, broadening the scope of precision radiotheranostics for prostate cancer.

Further validation using ex vivo human lymph node specimens confirmed its ability to selectively detect PSCA-positive metastases. With its ultrahigh contrast, demonstrated efficacy in intraoperative guidance, and strong translational potential, GGA-sNIR represents a promising molecular tool for advancing precision surgery in prostate cancer.

Depletion of Nkx6-3 occurred in the infected mice, indicating initiation of a pre-cancerous cascade. LCM RNA-Seq of SMCs was thus feasible and enabled characterization of the SMC and definition of a gene set showing how H. pylori infection affects SMCs.

Ongoing investigation into novel targets for the treatment of prostate cancer continues to identify promising antigens which are overexpressed on the cell surface. Patterns of expression may vary based on histologic type, anatomic location, and treatment state of prostate cancer, and these factors will ultimately dictate the utility of novel therapeutic agents that are in development.

Early studies in hematologic malignancies could provide a practical proof of concept, before tackling the additional challenges of solid tumors. Such focused development may be essential to advance the γδ CAR-T field amid tightening industry investment.

Finally, we designed a new synthetic co-stimulatory receptor that potentiates AP-1 activation resulting in improved in-vivo persistence. These results highlight fundamental biological differences between γδ and αβ T cells and support the development of cell type-specific receptor engineering strategies to maximize γδ CAR-T cell function and therapeutic benefit.

IDC-P possesses a distinct molecular and immunological profile. Understanding these molecular underpinnings is crucial for the development of personalized treatment strategies for histologically distinct prostate cancer subsets.

For example, genotypes at variants in the PSCA locus were perfectly predicted by urine PSCA levels and associated with PSCA expression and diseases of PSCA-expressing tissues, including bladder cancer and urinary tract infections, demonstrating potential clinical utility of urine protein levels. These findings are accessible through a convenient web application, and establish a comprehensive genetic framework for kidney protein handling to facilitate clinical and experimental investigations.

Additionally, this review aims to systematically summarize the relevant progress in this field. In conclusion, the findings provide a theoretical basis and clinical guidance for molecular-targeted therapy in PCa, thereby promoting further research and applications.

P1, N=21, Recruiting, City of Hope Medical Center | Trial completion date: Nov 2026 --> Nov 2028 | Trial primary completion date: Nov 2026 --> Nov 2028

Druggability analyses nominated several potential drug targets for PCa, such as HSPB1, RRM2B, and PSCA. Our findings reveal novel risk loci and candidate protein biomarkers, providing new etiological insights and potential avenues for PCa early detection and therapy.

BsAbs are a promising therapeutic strategy for mCRPC, with potential to improve outcomes in this poorly treatable disease. Addressing challenges (toxicity, tumor microenvironment, response durability) via research and trials is key to unlocking their full potential. Future research should focus on optimizing constructs, exploring novel targets, and developing combination therapies to advance BsAbs in prostate cancer.